Synapse - Hematologic Malignancies, Division of

Results (13365)

A phase 1 study of avapritinib in combination with decitabine in patients with systemic mastocytosis with an associated hematologic neoplasm

Meeting Abstract

Kuykendall, A. T.; Ball, S.; Gotlib, J.; Yi, C. Y. A.; Tashi, T.; Rampal, R.; DeAngelo, D. J.; Volpe, V. O.; Pettit, K. M.; Hoehn, G.; more...
Blood (2024)

Fulltext@MSK | Save

CTEP 10590, NORM: Nodular lymphocyte predominant Hodgkin lymphoma patients treated in a randomized phase II trial with either rituximab or mosunetuzumab

Meeting Abstract

Steiner, R.; Bock, A. M.; Herrera, A. F.; Zulfa, O.; Hoffmann, M.; Ibrahimi, S.; Galanina, N.; Lee, H. J.; Green, M.; Lin, R.; more...
Blood (2024)

Fulltext@MSK | Save

Phase 3, randomized, open-label study of epcoritamab plus lenalidomide compared with rituximab plus gemcitabine and oxaliplatin in patients with relapsed or refractory diffuse large B-cell lymphoma

Meeting Abstract

Ozcan, M.; Kim, W. S.; Zhang, H.; Bouzani, M.; Nagy, Z.; Chuah, H.; Salles, G.; Jeng, E. E.; Huang, J.; Sacchi, M.; more...
Blood (2024)

Fulltext@MSK | Save

A multi-site break through cancer trial: Phase II study investigating dual inhibition of BCL2 and menin in AML MRD using the combination of venetoclax and revumenib (trial in progress)

Meeting Abstract

Issa, G. C.; Ambinder, A. J.; Xiao, W.; Manalis, S.; Shalek, A. K.; Gondek, L. P.; Kentsis, A.; Short, N. J.; Daver, N.; Ning, J.; more...
Blood (2024)

Fulltext@MSK | Save

OPTIMIZE: A phase II study of reduced dose post transplantation cyclophosphamide as GVHD prophylaxis in adult patients with hematologic malignancies receiving HLA-mismatched unrelated donor peripheral blood stem cell transplantation

Meeting Abstract

Auletta, J. J.; Devine, S. M.; Stefanski, H. E.; Spellman, S. R.; Defor, T. E.; Logan, B. R.; Butler, B. J.; Gooptu, M.; Shaffer, B. C.; Jimenez, A. M. J.; more...
Blood (2024)

Fulltext@MSK | Save

CD38-SADA pretargeted radioimmunotherapy (PRIT) with Lutetium 177 (Lu177)-DOTA in adult patients with relapsed or refractory non-Hodgkin lymphoma: A first-in-human phase 1 trial

Meeting Abstract

Zain, J.; Wong, J.; Horwitz, S.; Pandit-Taskar, N.; Al-Janadi, A.; Mancini, B.; Khawaja, R.; Lee, C. Y.; Howansky, A.; Liles, D.; more...
Blood (2024)

Fulltext@MSK | Save

Results from the Great Britain AML real world evidence (ARC) initiative - A centre-based chart review study to assess treatment outcomes of venetoclax for the treatment of acute myeloid leukemia

Meeting Abstract

O'Nions, J.; Errico, G.; Floro, L.; Murthy, V.; Sweeney, C.; Kaur, H.; Mohite, U.; Ayto, R.; Alvares, C.; Goldberg, A. D.; more...
Blood (2024)

Fulltext@MSK | Save

A phase III, randomized study of daratumumab, cyclophosphamide, bortezomib and dexamethasone (DARA-VCD) induction followed by autologous stem cell transplant or Dara-VCD consolidation and daratumumab maintenance in patients with newly diagnosed AL amyloidosis

Meeting Abstract

Hagen, P.; Sidana, S.; Parker, T. L.; Walker, B. A.; Sanchorawala, V.; Zonder, J. A.; Kourelis, T.; D'Souza, A.; Landau, H. J.; Rosenthal, A.; more...
Blood (2024)

Fulltext@MSK | Save

Optimizing therapeutic outcome of CD19(T2)28z1XX chimeric antigen receptor (CAR) T in adult patients with large B-cell lymphoma through a quantitative medicine approach

Meeting Abstract

Dey, A.; Li, J.; Park, J. H.; Sellner, L.; Sundaresan, V.; Palomba, M. L.; Mansilla-Soto, J.; Senechal, B.; Wang, X.; Sikder, D. S.; more...
Blood (2024)

Fulltext@MSK | Save

Bridging radiotherapy may decrease inflammation prior to CAR-T cell therapy

Meeting Abstract

Patel, R. R.; Tward, A.; Fregonese, B.; Hubbeling, H.; Lapen, K.; Mankuzhy, N. P.; Raj, S. S.; Perales, M. A.; Shouval, R.; Yahalom, J.; more...
Blood (2024)

Fulltext@MSK | Save